文献速递慢性肾脏病血液净化与透析肾移植

慢性肾脏病患者带状疱疹疫苗的系统综述与荟萃分析

Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD.
PubMed 文献 · Kidney Int Rep · 2021-03-03

本研究系统检索并荟萃分析了8项对照研究(共404,561例肾脏病患者),评估带状疱疹疫苗在慢性肾脏病、透析及移植患者中的有效性与安全性。结果显示接种疫苗者带状疱疹风险显著降低(HR 0.55,95%CI 0.37-0.82,P<0.01),且不良事件无显著增加(HR 1.03,95%CI 0.54-1.28,P=0.8),但异质性较高(I²=88%)。

要点

  • 慢性肾脏病患者接种带状疱疹疫苗可显著降低带状疱疹风险(HR 0.55)。
  • 疫苗相关不良事件风险与对照相比无显著差异(HR 1.03)。
  • 研究间异质性高(I²=88%),结论需谨慎解读。

核心结论

  • 在慢性肾脏病患者中,带状疱疹疫苗相比对照可显著降低带状疱疹风险,且不增加不良事件。
  • 鉴于慢性肾脏病人群带状疱疹患病率较高,应积极考虑接种带状疱疹疫苗。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase和Cochrane CENTRAL数据库(截至2020年5月)。
  • 纳入8项对照研究(3项随机对照试验和5项非随机对照研究),共404,561例肾脏病患者(慢性肾脏病、透析和移植)。
  • 排除无对照组(安慰剂或无疫苗)的研究;采用随机效应模型合并治疗效应和95%置信区间。

主要发现

  • 所有8项研究均评估带状疱疹结局,其中3项报告不良事件。
  • 接种带状疱疹疫苗者带状疱疹风险低于对照(风险比0.55;95%CI 0.37-0.82;P<0.01)。
  • 异质性较高(I²=88%,P<0.01)。
  • 疫苗相关不良事件风险与对照无显著差异(风险比1.03;95%CI 0.54-1.28;P=0.8)。

临床怎么用

  • 对于慢性肾脏病患者,应积极考虑接种带状疱疹疫苗以降低带状疱疹风险。
  • 接种时需注意研究间异质性较高,个体化评估获益与风险。

局限性

  • 纳入研究间异质性高(I²=88%)。
  • 仅3项研究报告不良事件,安全性数据有限。
  • 纳入非随机对照研究可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease (CKD) is a risk factor for herpes zoster (HZ) infection. Few studies have examined HZ vaccine (HZV) in this population. We conducted a systematic review and meta-analysis investigating the efficacy and safety of HZV in patients with renal disease (CKD, dialysis, and transplant). METHODS: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) databases (up to May 2020) were searched for randomized controlled trials and nonrandomized controlled studies evaluating HZV in patients with CKD for effectiveness and adverse event risks. Studies without a control group (placebo or no vaccine) were excluded. Extraction of prespecified data and risk of bias assessments using the Newcastle-Ottawa scale for cohort studies and the Cochrane Risk of Bias Tool for randomized controlled trials were done by 3 authors. Random-effects meta-analysis was used to generate pooled treatment effects and 95% confidence intervals. RESULTS: Included were 404,561 individuals from 8 studies (3 randomized controlled trials and 5 nonrandomized). All 8 studies examined HZ as an outcome, with 3 reporting adverse events. Risk of HZ was lower in patients who received HZV compared with controls (hazard ratio, 0.55; 95% confidence interval, 0.37-0.82; P < 0.01); however, heterogeneity was high (I 2 = 88%, P < 0.01). There was no significant difference in adverse events associated with HZV (hazard ratio, 1.03; 95% confidence interval, 0.54-1.28; P = 0.8). CONCLUSIONS: HZV compared with control significantly lowers the risk of HZ without an increase in adverse events in CKD patients. However, significant heterogeneity was present. HZV should be actively considered in CKD patients because the prevalence of HZ is higher in this population.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Hamad MA, Allam H, Sulaiman A, et al. Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD. Kidney Int Rep. 2021. PMID: 34013103. doi:10.1016/j.ekir.2021.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。